Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].
Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AG, Califf RM, Weatherley B, Cohen M. Mark DB, et al. Among authors: califf rm. Circulation. 1998 May 5;97(17):1702-7. doi: 10.1161/01.cir.97.17.1702. Circulation. 1998. PMID: 9591764 Clinical Trial.
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM. Mark DB, et al. Among authors: califf rm. Circulation. 1996 Aug 15;94(4):629-35. doi: 10.1161/01.cir.94.4.629. Circulation. 1996. PMID: 8772681 Clinical Trial.
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.
Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, Armstrong PW, Topol EJ, Califf RM. Berkowitz SD, et al. Among authors: califf rm. Circulation. 1997 Jun 3;95(11):2508-16. doi: 10.1161/01.cir.95.11.2508. Circulation. 1997. PMID: 9184581
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, Mahaffey KW, White H, Clapp-Channing N, Simoons ML, Gore JM, Califf RM, Mark DB. Tung CY, et al. Among authors: califf rm. Circulation. 1999 Jan 26;99(3):370-6. doi: 10.1161/01.cir.99.3.370. Circulation. 1999. PMID: 9918523
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA. McClure MW, et al. Among authors: califf rm. Circulation. 1999 Jun 8;99(22):2892-900. doi: 10.1161/01.cir.99.22.2892. Circulation. 1999. PMID: 10359733 Clinical Trial.
1,330 results